Cancer and dermatology specialist Provectus Biopharmaceuticals (NYSE:PVCT) highlighted data has been released on the immunology effects of its PV-10 treatment in colon cancer cells.
PV-10 is a treatment designed to be injected into solid tumours, particularly in melanoma, breast cancer and cancers of the liver, lowering the risk of potential side effects.
The research note - PV-10 Induces Potent Immunogenic Apoptosis in Colon Cancer Cells – was presented at the 11th Annual Academic Surgical Congress in Jacksonville, Florida.
The presentation, made by Dr Kunda from the University of Illinois, noted that in vitro testing of PV-10 on colon cancer showed it was toxic to the cancerous cells.
Dr Eric Wachter, chief technological officer of Provectus, said: “The work reported in Dr. Kunda’s presentation further expands our understanding of the mechanism of action of PV-10 as an ablative immunotherapy for solid tumors, and parallels immunologic signaling noted upon ablation of melanoma with PV-10.”